| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Pathology and Laboratory Medicine [C. C., A. Z-P., J. H. S., D. G. S., N. M.], Hematology/Oncology [M. S.], Public Health, Division of Biostatistics [G. C.], and Dermatology [F. C., B. G., J. L. A.], Emory University School of Medicine, and Veterans Administration Hospital, Atlanta, Georgia 30322 [F. C., B. G., J. L. A.]
Purpose: Melanoma is the most common cause of death from cutaneous malignancy, and is the cancer that is most rapidly rising in incidence. Because current therapeutic methods for metastatic melanoma are poorly efficacious, enhanced understanding of signal transduction in melanoma progression is warranted. Prior experimental studies in murine models and human tissues have shown a correlation among activation of mitogen activated protein kinase (MAPK) signaling, angiogenesis, and tumorigenesis. Because of these findings, we wanted to assess the role of MAPK signaling in melanoma progression and angiogenesis.
Experimental Design: We studied expression of phosphorylated (active) MAPK and two target genes known to be induced by MAPK signaling, tissue factor and vascular endothelial growth factor, in 131 melanocytic lesions, ranging from atypical nevi to metastatic melanoma.
Results: We observed little staining for activated (phosphorylated) MAPK and low amounts of angiogenesis in atypical nevi, but angiogenesis and MAPK activation were activated in radial growth melanoma and in later stage lesions.
Conclusions: Our findings implicate MAPK activation as an early event in melanoma progression, and MAPK may be a potential target for pharmacologic intervention.
This article has been cited by other articles:
|
|
 |
|
  W. Maat, S. H. W. Beiboer, M. J. Jager, G. P. M. Luyten, N. A. Gruis, and P. A. van der Velden Epigenetic Regulation Identifies RASEF as a Tumor-Suppressor Gene in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1291 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mashiah, Y. Wohl, Y. Barnea, S. Schneebaum, A. Gat, F. Misonzhnik-Bedny, and S. Brenner Immunohistochemical Expression of Platelet Growth Factor and Vascular Endothelial Growth Factor in Patients With Melanoma With and Without Redness (Brenner Sign) Arch Dermatol, August 1, 2007; 143(8): 1001 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schwartz, O. Shoseyov, V. O. Melnikova, M. McCarty, M. Leslie, L. Roiz, P. Smirnoff, G.-f. Hu, D. Lev, and M. Bar-Eli ACTIBIND, a T2 RNase, Competes with Angiogenin and Inhibits Human Melanoma Growth, Angiogenesis, and Metastasis Cancer Res., June 1, 2007; 67(11): 5258 - 5266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yancovitz, J. Yoon, M. Mikhail, W. Gai, R. L. Shapiro, R. S. Berman, A. C. Pavlick, P. B. Chapman, I. Osman, and D. Polsky Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma J. Mol. Diagn., April 1, 2007; 9(2): 178 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Mhaidat, X. D. Zhang, C. C. Jiang, and P. Hersey Docetaxel-Induced Apoptosis of Human Melanoma Is Mediated by Activation of c-Jun NH2-Terminal Kinase and Inhibited by the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 1/2 Pathway Clin. Cancer Res., February 15, 2007; 13(4): 1308 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Wattenberg Palytoxin: exploiting a novel skin tumor promoter to explore signal transduction and carcinogenesis Am J Physiol Cell Physiol, January 1, 2007; 292(1): C24 - C32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kono, I. S. Dunn, P. J. Durda, D. Butera, L. B. Rose, T. J. Haggerty, E. M. Benson, and J. T. Kurnick Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression Mol. Cancer Res., October 1, 2006; 4(10): 779 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Perry, C. Cohen, B. Govindarajan, G. Cotsonis, and J. L. Arbiser Wilms tumor 1 expression present in most melanomas but nearly absent in nevi. Arch Dermatol, August 1, 2006; 142(8): 1031 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Zhuang, C S Lee, R A Scolyer, S W McCarthy, A A Palmer, X D Zhang, J F Thompson, L P Bron, and P Hersey Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma J. Clin. Pathol., November 1, 2005; 58(11): 1163 - 1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Lawley, F. Cerimele, S. W. Weiss, P. North, C. Cohen, H. P. W. Kozakewich, J. B. Mulliken, and J. L. Arbiser Expression of Wilms Tumor 1 Gene Distinguishes Vascular Malformations From Proliferative Endothelial Lesions Arch Dermatol, October 1, 2005; 141(10): 1297 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Govindarajan, A. Shah, C. Cohen, R. S. Arnold, J. Schechner, J. Chung, A. M. Mercurio, R. Alani, B. Ryu, C.-Y. Fan, et al. Malignant Transformation of Human Cells by Constitutive Expression of Platelet-derived Growth Factor-BB J. Biol. Chem., April 8, 2005; 280(14): 13936 - 13943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cerimele, T. Battle, R. Lynch, D. A. Frank, E. Murad, C. Cohen, N. Macaron, J. Sixbey, K. Smith, R. S. Watnick, et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma PNAS, January 4, 2005; 102(1): 175 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Warmka, L. J. Mauro, and E. V. Wattenberg Mitogen-activated Protein Kinase Phosphatase-3 Is a Tumor Promoter Target in Initiated Cells That Express Oncogenic Ras J. Biol. Chem., August 6, 2004; 279(32): 33085 - 33092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Schuierer, F. Bataille, S. Hagan, W. Kolch, and A.-K. Bosserhoff Reduction in Raf Kinase Inhibitor Protein Expression Is Associated with Increased Ras-Extracellular Signal-Regulated Kinase Signaling in Melanoma Cell Lines Cancer Res., August 1, 2004; 64(15): 5186 - 5192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vicent, M. Garayoa, J. M. Lopez-Picazo, M. D. Lozano, G. Toledo, F. B. J. M. Thunnissen, R. G. Manzano, and L. M. Montuenga Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients Clin. Cancer Res., June 1, 2004; 10(11): 3639 - 3649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Eisenmann, M. W. VanBrocklin, N. A. Staffend, S. M. Kitchen, and H.-M. Koo Mitogen-Activated Protein Kinase Pathway-Dependent Tumor-Specific Survival Signaling in Melanoma Cells through Inactivation of the Proapoptotic Protein Bad Cancer Res., December 1, 2003; 63(23): 8330 - 8337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ma, J. Wang, and J. Luo Exposure to Asphalt Fumes Activates Activator Protein-1 through the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway in Mouse Epidermal Cells J. Biol. Chem., November 7, 2003; 278(45): 44265 - 44272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Collisson, A. De, H. Suzuki, S. S. Gambhir, and M. S. Kolodney Treatment of Metastatic Melanoma with an Orally Available Inhibitor of the Ras-Raf-MAPK Cascade Cancer Res., September 15, 2003; 63(18): 5669 - 5673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Conner, G. Scott, and A. E. Aplin Adhesion-dependent Activation of the ERK1/2 Cascade Is By-passed in Melanoma Cells J. Biol. Chem., September 5, 2003; 278(36): 34548 - 34554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Handra-Luca, H. Bilal, J.-C. Bertrand, and P. Fouret Extra-Cellular Signal-Regulated ERK-1/ERK-2 Pathway Activation in Human Salivary Gland Mucoepidermoid Carcinoma: Association to Aggressive Tumor Behavior and Tumor Cell Proliferation Am. J. Pathol., September 1, 2003; 163(3): 957 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Govindarajan, M. C. Mizesko, M. S. Miller, H. Onda, M. Nunnelly, K. Casper, D. Brat, C. Cohen, and J. L Arbiser Tuberous Sclerosis-associated Neoplasms Express Activated p42/44 Mitogen-activated Protein (MAP) Kinase, and Inhibition of MAP Kinase Signaling Results in Decreased in Vivo Tumor Growth Clin. Cancer Res., August 1, 2003; 9(9): 3469 - 3475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gorden, I. Osman, W. Gai, D. He, W. Huang, A. Davidson, A. N. Houghton, K. Busam, and D. Polsky Analysis of BRAF and N-RAS Mutations in Metastatic Melanoma Tissues Cancer Res., July 15, 2003; 63(14): 3955 - 3957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Govindarajan, X. Bai, C. Cohen, H. Zhong, S. Kilroy, G. Louis, M. Moses, and J. L Arbiser Malignant Transformation of Melanocytes to Melanoma by Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MAPKK) Signaling J. Biol. Chem., March 7, 2003; 278(11): 9790 - 9795. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
